Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV002359471 | SCV002619646 | uncertain significance | Hereditary cancer-predisposing syndrome | 2020-10-15 | criteria provided, single submitter | clinical testing | The p.A134G variant (also known as c.401C>G), located in coding exon 2 of the CDKN2A gene, results from a C to G substitution at nucleotide position 401. The alanine at codon 134 is replaced by glycine, an amino acid with similar properties. This amino acid position is poorly conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |